Home Journals A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of an Omega-3 Fatty Acid Supplement in Patients With Predialysis Chronic Kidney Disease

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of an Omega-3 Fatty Acid Supplement in Patients With Predialysis Chronic Kidney Disease

Credits to the Source Link Obum
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of an Omega-3 Fatty Acid Supplement in Patients With Predialysis Chronic Kidney Disease
    • Jha V.
    • Garcia-Garcia G.
    • Iseki K.
    • et al.

    Chronic kidney disease: global dimension and perspectives.

    Lancet. 2013; 382: 260-272

    • Zúñiga S.M.C.
    • Müller O.H.
    • Flores O.M.

    Rev Med Chil. 2011; 139: 1176-1184

  • KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.

    Kidney Int Suppl. 2013; 3: 1-150

    • Gansevoort R.T.
    • Correa-Rotter R.
    • Hemmelgarn B.R.
    • et al.

    Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.

    Lancet. 2013; 382: 339-352

    • Coresh J.
    • Turin T.C.
    • Matsushita K.
    • et al.

    Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality.

    JAMA. 2014; 311: 2518-2531

    • Rios A.
    • Lorca E.
    • Garmendia M.L.
    • et al.

    Estimated glomerular filtration rate, urine albumin excretion, and survival among patients consulting in public Chilean public primary care clinics.

    Ren Fail. 2016; 38: 397-403

    • James M.
    • Hemmelgarn B.
    • Tonelli M.

    Early recognition and prevention of chronic kidney disease.

    Lancet. 2010; 375: 1296-1309

    • Shapiro H.
    • Theilla M.
    • Attal-Singer J.
    • Singer P.

    Effects of polyunsaturated fatty acid consumption in diabetic nephropathy.

    Nat Rev Nephrol. 2011; 7: 110-121

    • Theuer J.
    • Shagdarsuren E.
    • Muller D.N.
    • et al.

    Inducible NOS inhibition, eicosapentaenoic acid supplementation, and angiotensin II-induced renal damage.

    Kidney Int. 2005; 67: 248-258

    • Lee C.T.
    • Adler A.I.
    • Forouhi N.G.
    • et al.

    Cross-sectional association between fish consumption and albuminuria: the European Prospective Investigation of Cancer-Norfolk Study.

    Am J Kidney Dis. 2008; 52: 876-886

    • Cárdenas C.
    • Bordiu E.
    • Bagazgoitia J.
    • Calle-Pascual A.L.
    • Diabetes and Nutrition Study Group, Spanish Diabetes Association

    Polyunsaturated fatty acid consumption may play a role in the onset and regression of microalbuminuria in well-controlled type 1 and type 2 diabetic people: a 7-year, prospective, population-based, observational multicenter study.

    Diabetes Care. 2004; 27: 1454-1457

    • Elajami T.K.
    • Alfaddagh A.
    • Lakshminarayan D.
    • Soliman M.
    • Chandnani M.
    • Welty F.K.

    Eicosapentaenoic and docosahexaenoic acids attenuate progression of albuminuria in patients with type 2 diabetes mellitus and coronary artery disease.

    J Am Heart Assoc. 2017; 6: e004740

    • Jensen T.
    • Stender S.
    • Goldstein K.
    • Hølmer G.
    • Deckert T.

    Partial normalization by dietary cod-liver oil of increased microvascular albumin leakage in patients with insulin-dependent diabetes and albuminuria.

    N Engl J Med. 1989; 321: 1572-1577

    • Rossing P.
    • Hansen B.V.
    • Nielsen F.S.
    • Myrup B.
    • Hølmer G.
    • Parving H.H.

    Fish oil in diabetic nephropathy.

    Diabetes Care. 1996; 19: 1214-1219

    • Pettersson E.E.
    • Rekola S.
    • Berglund L.
    • et al.

    Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study.

    Clin Nephrol. 1994; 41: 183-190

    • Donadio Jr., J.V.
    • Grande J.P.
    • Bergstralh E.J.
    • Dart R.A.
    • Larson T.S.
    • Spencer D.C.

    The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group.

    J Am Soc Nephrol. 1999; 10: 1772-1777

    • Matusheski N.V.
    • Marshall K.
    • Hartunian-Sowa S.
    • McBurney M.I.

    US family physicians overestimate personal Ω-3 fatty acid biomarker status: associations with fatty fish and Ω-3 supplement intake.

    Curr Dev Nutr. 2017; 2: nzx007

    • Waikar S.S.
    • Rebholz C.M.
    • Zheng Z.
    • et al.

    Biological variability of estimated GFR and albuminuria in CKD.

    Am J Kidney Dis. 2018; 72: 538-546

    • Reinders I.
    • Murphy R.A.
    • Song X.
    • et al.

    Higher plasma phospholipid n-3 PUFAs, but lower n-6 PUFAs, are associated with lower pulse wave velocity among older adults.

    J Nutr. 2015; 145: 2317-2324

    • Pickup L.
    • Radhakrishnan A.
    • Townend J.N.
    • Ferro C.J.

    Arterial stiffness in chronic kidney disease: a modifiable cardiovascular risk factor?.

    Curr Opin Nephrol Hypertens. 2019; 28: 527-536

    • Hashimoto J.
    • O’Rourke M.F.

    Inflammation and arterial stiffness in chronic kidney disease: cause or consequence?.

    Am J Hypertens. 2017; 30: 350-352

    • Tsuruya K.
    • Yoshida H.
    • Nagata M.
    • et al.

    Association of the triglycerides to high-density lipoprotein cholesterol ratio with the risk of chronic kidney disease: analysis in a large Japanese population.

    Atherosclerosis. 2014; 233: 260-267

    • Writing Committee Members
    • Yancy C.W.
    • Jessup M.
    • et al.
    • American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

    2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

    Circulation. 2013; 128: e240-e327

  • A rapid method of total lipid extraction and purification.

    Can J Biochem Physiol. 1959; 37: 911-917

    • Harris W.S.
    • Sands S.A.
    • Windsor S.L.
    • Ali H.A.
    • et al.

    Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation.

    Circulation. 2004; 110: 1645-1649

    • Benas D.
    • Kornelakis M.
    • Triantafyllidi H.
    • et al.

    Pulse wave analysis using the Mobil-O-Graph, Arteriograph and Complior device: a comparative study.

    Blood Press. 2019; 28: 107-113

    • Stein J.H.
    • Korcarz C.E.
    • Post W.S.

    Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: summary and discussion of the American Society of Echocardiography consensus statement.

    Prev Cardiol. 2009; 12: 34-38

    • Davivian M.
    • Giltinan D.M.

    Analysis of repeated measurement data using the non linear mixed effects model.

    Chemometrics Intell Lab Syst. 1993; 20: 1-24

    • Mima A.
    • Yasuzawa T.
    • King G.L.
    • Ueshima S.

    Obesity-associated glomerular inflammation increases albuminuria without renal histological changes.

    FEBS Open Bio. 2018; 8: 664-670

  • Omega-3 fatty acids, cardiovascular risk, and the resolution of inflammation.

    FASEB J. 2019; 33: 1536-1539

    • Miller 3rd, E.R.
    • Juraschek S.P.
    • Appel L.J.
    • et al.

    The effect of n-3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: meta-analysis of clinical trials.

    Am J Clin Nutr. 2009; 89: 1937-1945

    • de Boer I.H.
    • Zelnick L.R.
    • Ruzinski J.
    • et al.

    Effect of vitamin D and omega-3 fatty acid supplementation on kidney function in patients with type 2 diabetes: a randomized clinical trial.

    JAMA. 2019; 322: 1899-1909

    • Georgianos P.I.
    • Sarafidis P.A.
    • Lasaridis A.N.

    Arterial stiffness: a novel cardiovascular risk factor in kidney disease patients.

    Curr Vasc Pharmacol. 2015; 13: 229-238

    • Ito R.
    • Satoh-Asahara N.
    • Yamakage H.
    • et al.

    An increase in the EPA/AA ratio is associated with improved arterial stiffness in obese patients with dyslipidemia.

    J Atheroscler Thromb. 2014; 21: 248-260

    • Tousoulis D.
    • Plastiras A.
    • Siasos G.
    • et al.

    Omega-3 PUFAs improved endothelial function and arterial stiffness with a parallel antiinflammatory effect in adults with metabolic syndrome.

    Atherosclerosis. 2014; 232: 10-16

  • Arterial stiffness in CKD: a review.

    Am J Kidney Dis. 2019; 73: 240-247

    • Ushigome E.
    • Fukui M.
    • Hamaguchi M.
    • et al.

    Maximum home systolic blood pressure is a useful indicator of arterial stiffness in patients with type 2 diabetes mellitus: post hoc analysis of a cross-sectional multicenter study.

    Diabetes Res Clin Pract. 2014; 105: 344-345

    • Tsuruya K.
    • Yoshida H.
    • Nagata M.
    • et al.

    Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of CKD: a longitudinal study in a large Japanese population.

    Am J Kidney Dis. 2015; 66: 972-983

    • Navaneethan S.D.
    • Schold J.D.
    • Arrigain S.
    • et al.

    Serum triglycerides and risk for death in Stage 3 and Stage 4 chronic kidney disease.

    Nephrol Dial Transpl. 2012; 27: 3228-3234

    • Friday K.E.
    • Childs M.T.
    • Tsunehara C.H.
    • Fujimoto W.Y.
    • Bierman E.L.
    • Ensinck J.W.

    Elevated plasma glucose and lowered triglyceride levels from omega-3 fatty acid supplementation in type II diabetes.

    Diabetes Care. 1989; 12: 276-281

    • Hartweg J.
    • Perera R.
    • Montori V.
    • Dinneen S.
    • Neil H.A.
    • Farmer A.

    Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus.

    Cochrane Database Syst Rev. 2008; : CD003205

    • Bhatt D.L.
    • Steg P.G.
    • Miller M.
    • et al.

    Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.

    N Engl J Med. 2019; 380: 11-22

  • Source Link

    Related Posts

    Leave a Comment

    This website uses cookies to improve your experience. We will assume you are ok with this, but you can opt-out if you wish. Accept Read More

    %d bloggers like this: